Compared to vehicle treated T1DM mice, T1DM mice treated with canagliflozin had reduced bone formation, increased bone resorption, exaggerated urinary mineral loss, and a secondary increase in FGF23.(39) Additional experimental studies in models of T2DM and T2DM with CKD are needed to further define the effect of Sglt2 inhibition on bone health and to assess differences between genetic loss of function and drug‐induced inhibition. The gene discussed is FGF23; the disease is chronic kidney disease.